METHOD FOR DETECTING A PROSTATE CANCER BIOMARKER

The present disclosure relates to a method for detecting a prostate cancer related biomarker, including contacting the diluted sample with a modulating agent selected from a group consisting of sodium; 3-hydroxy-4-[(2-hydroxynaphthalen-1-yl)diazenyl]naphthalene-1-sulfonate, sodium; 3-hydroxy-4-[(1-hydroxynaphthalen-2-yl)diazenyl]-7-nitronaphthalene-1-sulfonate, triisopropylsilane, and iron(III) chloride, and a luminescent label to obtain a measurement sample. Then, the measurement sample is incubated for a period of time and excited thereafter. Time-resolved luminescence signal of the label in the measurement sample is measured, leading to an increased likelihood of prostate cancer of the human subject if the luminescence signal is at least 50% higher than for a control sample from a human subject without prostate cancer.